(Adnkronos) - “La ricerca sul parkinson si sta concentrando su farmaci che possono rallentare o bloccare il decorso di malattia e, per questo, si stanno studiando degli anticorpi monoclonali che possano catturare la proteina che causa la malattia, ovvero l'alfa sinucleina, o bloccarne l'aggregazione”. Lo afferma Fabrizio Stocchi, professore ordinario università San Raffaele di Roma, in occasione del 54° Congresso Sin - Società italiana di neurologia, in svolgimento a Roma fino al 12 novembre.
Category
🗞
NewsTranscript
00:00The Parkinson's disease is a very frequent disease, even among young people.
00:09Research is focusing on drugs that can slow or block the course of the disease,
00:16and for this reason, monoclonal antibodies are being studied that can capture the protein
00:22that causes the disease, namely alpha-synuclein, or block its aggregation.
00:27The results of these studies will be available next year.
00:32In the meantime, we are also focusing on improving the symptomatic therapy,
00:37because there are still 400,000 patients with Parkinson's disease in Italy
00:41who must be treated in the best possible way,
00:44and for this reason there are new formulations of drugs, new formulations of levodopa,
00:49drugs that can give an immediate effect, new dopamine agonists,
00:55drugs that do not only work on the dopaminergic system, as has been done so far,
01:00but also on other systems.